| Overview |
| bsm-63055r-rbitc-100ul |
| ATM Recombinant Antibody, RBITC Conjugated |
| WB, IF, Flow-Cyt |
| Human |
| Specifications |
| RBITC |
| Rabbit |
| Recombinant |
| IgG |
| Lot Dependent |
| Purified by Protein A. |
| Aqueous buffered solution containing 0.01M TBS (pH7.4) with 1% BSA, 0.02% Proclin300 and 50% Glycerol. |
| Store at -20°C. Aliquot into multiple vials to avoid repeated freeze-thaw cycles. |
| Target |
| 472 |
| Q13315 |
| ataxia telangiectasia mutated; AT complementation group A; AT complementation group C; AT complementation group D; AT complementation group E; AT mutated; AT protein; AT1; ATA; Ataxia telangiectasia gene mutated in human beings; ATC; ATDC; ATE; ATM; DKFZp781A0353; Human phosphatidylinositol 3 kinase homolog; MGC74674; Serine protein kinase ATM; T cell prolymphocytic leukemia; TEL1; TPLL. |
| ATM is a 370 kDa nuclear phosphoprotein involved in the autosomal recessive disease Ataxia Telangiectasia (AT). ATM belongs to a novel family of proteins associated with cell cycle regulation, apoptosis, and response to DNA damage repair (DNA damage caused by such things as ionizing irradiation activates ATM kinase). The C terminal region has extensive homology to the catalytic domains of Phosphatidylinositol 3 kinases (PI3 kinases). |
| Application Dilution |
| WB |
1:300-5000 |
| IF |
|
| Flow-Cyt |
1ug/Test |
Powered by Bioz